LB1148 is a broad-spectrum serine protease inhibitor which neutralises digestive enzymes. Credit: Design_Cells via Shutterstock.com.

Palisade Bio has initiated enrolment and dosing of patients in its dose optimisation clinical trial of LB1148, a broad-spectrum serine protease inhibitor.

The company’s lead programme, LB1148, neutralises digestive enzymes thereby reducing damage to the intestine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study is designed to determine if a different dosing protocol for all indications might improve LB1148’s risk profile while providing efficacy at the same time.

It intends to enrol over 32 healthy subjects.

LB1148’s previous clinical studies have showed positive results in reducing the severity of post-surgical abdominal adhesions.

They also demonstrated that treatment with LB1148 potentially reduced the time to return of postoperative bowel function.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Palisade Bio interim CEO J.D. Finley said: “The dose optimisation study is designed to generate valuable pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers.

“We believe the outcome of this study will add to our growing body of data and provide the line of sight needed to further guide our LB1148 clinical development strategy moving forward.”

The company intends to complete patient enrolment in LB1148’strial in the third quarter of this year.

The company’s Phase II study currently underway is evaluating LB1148’s effectiveness in reducing intra-abdominal adhesions, and accelerating return of gastrointestinal function.

The study is also demonstrating LB1148’s effectiveness in the prevention of post-operative ileus in subjects who are undergoing elective bowel resection.